Aristro Capital Markets Ltd.
You Are On :   Home  |  Equity  |   Company Profile  |  Board Meetings
 
Equity
Equity Analysis
Price
Volume
Analysis
News Analysis
Corporate Action
Other Market
Company Profile
Board Meetings
Bacil Pharma Ltd.
 
BSE Code 524516
ISIN Demat INE711D01018
Book Value (Rs.) 17.55
NSE Code NA
Dividend Yield  % 0.00
Market Cap  (Rs. Mn) 269.12
TTM PE (x) 17.31
TTM EPS (Rs.) 1.08
Face Value (Rs.) 10  
Source DateBoard Meeting DateDetails
03-Jul-2026 09-Jul-2026 Inter alia, to consider and approve the following:- 1. The proposal for raising funds by way of a Rights Issue of equity shares to the eligible equity shareholders of the Company for an aggregate amount of up to Rs.50,00,00,000 (Rupees Fifty Crores Only), in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, subject to such statutory and regulatory approvals as may be required. 2. The proposal for increase in the Authorised Share Capital of the Company, if required, to facilitate the proposed Rights Issue and to ensure adequate headroom for issuance of equity shares pursuant thereto. 3. Consequent alteration of the Capital Clause of the Memorandum of Association of the Company and other related documents, if required, subject to the approval of the Board and the shareholders of the Company, as applicable. 4. To determine and approve the detailed terms and conditions of the Rights Issue, including but not limited to the issue size, rights entitlement ratio, issue price, record date, rights issue schedule, appointment of intermediaries, draft Letter of Offer and such other matters incidental or connected therewith. 5. Discussion on Appointment and Resignation of Directors. 6. Any other matter incidental or connected with the proposed Rights Issue and increase in the Authorised Share Capital
23-Jun-2026 26-Jun-2026 Inter alia, to consider and evaluate proposals for raising funds by the Company through one or more permissible modes, subject to such statutory and regulatory approvals as may be required, including but not limited to: 1.. Preferential Issue (including preferential allotment of equity shares and/or convertible securities); 2. Rights Issue; Any other permissible mode or combination thereof, as may be considered appropriate by the Board, in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws. The Board may also consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman
11-May-2026 22-May-2026 Audited Results
05-Feb-2026 13-Feb-2026 Quarterly Results
06-Nov-2025 13-Nov-2025 Quarterly Results
02-Sep-2025 05-Sep-2025 Inter alia, To discuss and approve the following matters: ? Discussion on Notice for 38th Annual General Meeting for the Company. ? Discussion on Director Report of the Company for the Financial Year 2024-2025. ? Discussion to Fix Date, Place and Timing of 38th Annual General Meeting of the Company ? Discussion on matter related to Loan to Equity shares of the Company. ? Any other business with the permission of Chairperson.
19-Aug-2025 25-Aug-2025 Inter alia, to consider and approve:- 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson.
05-Aug-2025 12-Aug-2025 Quarterly Results
11-Jul-2025 16-Jul-2025 Inter alia, to consider and approve:- 1. To consider and discuss the appointment of a new Executive Director and Chief Financial Officer (CFO) of the Company; 2. To consider and discuss the resignation of the present Chief Financial Officer (CFO) of the Company. 3. Any other business with the permission of chair.
19-May-2025 26-May-2025 Audited Results
close X

Download Client Registration Documents

Client Registration Documents in Vernacular Languages

Member: NSE CAPITAL MARKET: INB231498438 | NSE FUTURE & OPTION: INF231498438 | BSE CAPITAL MARKET: INB011498434 | BSE FUTURE MARKET: INF011498434 | DP REGN No.:IN-DP-CDSL-704-2013 | Single SEBI Registration nos.: NSE & BSE: INZ000219238 | DP CDSL: IN-DP-407-2019
Attention Investor: Update your mobile number and email id with your stock broker.
Home| About Us | Services | Login | Research | Online Trading | Customer Support | Useful links | SEBI SCORE | Contact Us | Investor Charter | Share Links:  
Terms & Conditions |Disclaimer | Privacy Policy |Policy & Procedure | Feedback | Open An Account | Downloads |Customer Desk |Policy |Site Map |Segregation and Monitoring of Collateral
NSE | BSE | SEBI | NSDL | NCDEX | CDSL | MCX | NMCE | MCX-SX | RBI | Do & Don'ts | CDSL Circular | CDSL e-Voting | Rights & Obligations | Risk Disclousre Document
Details of Authorised Persons | Basic Details | SMART ODR | Policy on Handling of GTC Orders | Saral Account opening form | Rights and Obligation for DP
QR Code for DP | QR Code for Stock Broker | ARISTRO MGT7 | CSR Policy Aristro | Investor Charter-Stock Broker | Grievance
Copyright Aristro Capital Markets Ltd. All Rights Reserved.
Designed, Developed & Content Powered By  Accord Fintech Pvt. Ltd.